Onconetix Inc (ONCE) Quote

Congrats!

great buyout, congrats to all !!

To the Moon Alice!!

Glad I loaded up some more shares at the low this morning.

Almost a it’s 52 week high!

Horribly low volume here....Ughk.

Too close to call but it appears we might be trying to break passed the 50.30 roadblock.

Bought some 50 puts this morning and wrote some 40 puts.
Also bought a few fair priced further out calls in case we reverse big in the next few weeks. Pretty well covered for either direction.

Nope....still ugly...ugly

How about a 53.20 close?

Might be getting setup...

Sold some puts I thought were kaput! Booyah!

Where’s all the excited share holders? Why are you all so quiet? This is the time to be excited!
Spark is going up! Watch next week soar

18 polled investment analysts is to buy stock in Spark Therapeutics Inc.

http://money.cnn.com/quote/forecast/forecast.html?symb=ONCE

Not bad at all.

Great news..

IMO

BOOM!!!!!!

Merry Christmas here! $$$$$
ONCE is giving sight to the blind! Literally

“Spark also received the 13th Rare Pediatric Disease Priority Review Voucher, issued by the FDA to incentivize work on rare pediatric diseases. Just 24 hours ago, Ultragenyx sold its voucher to Novartis for a cool $130 million. A voucher can be exchanged for priority review of any drug in the company’s pipeline — an alluring prospect when competition is tight.”

https://medcitynews.com/2017/12/gene-therapies-are-on-fire/?rf=1

Indeed

Time to Buy! CBS news link below. Huge earning potential here. This stock is going to reach a new all time high in the coming months.
Where’s all my excited share holders??

https://www.cbsnews.com/news/gene-therapy-drug-rpe65-blindness-luxturna-spark-therapeutics/

Holding long here. Spark will rise above its previous high once people realize the FDA approval was obtained.
Buy now, this is an amazing price for Spark! People selling must be asleep.

FDA approved! Huge News! Luxturna is the first gene therapy approved in the U.S. to target a disease caused by mutations in a specific gene.
This is a huge step for Sparks Therapeutic.

Spark Therapeutics achieves gene therapy breakthrough.The approval gives hope to patients suffering from genetic retinal diseases as well as other genetic disorders.

Spark's, Luxturna, approved by FDA for treatment of inherited retinal disorder RPE65 a cause of the genetic disorder also known as Leber's Congenital Amaurosis.

"The U.S. Food and Drug Administration today approved Luxturna (voretigene neparvovec-rzyl), a new gene therapy, to treat children and adult patients with an inherited form of vision loss that may result in blindness. Luxturna is the first directly administered gene therapy approved in the U.S. that targets a disease caused by mutations in a specific gene."

Today’s approval marks another first in the field of gene therapy — both in how the therapy works and in expanding the use of gene therapy beyond the treatment of cancer to the treatment of vision loss — and this milestone reinforces the potential of this breakthrough approach in treating a wide-range of challenging diseases. The culmination of decades of research has resulted in three gene therapy approvals this year for patients with serious and rare diseases. I believe gene therapy will become a mainstay in treating, and maybe curing, many of our most devastating and intractable illnesses,” said FDA Commissioner Scott Gottlieb, M.D. “We’re at a turning point when it comes to this novel form of therapy and at the FDA, we’re focused on establishing the right policy framework to capitalize on this scientific opening. Next year, we’ll begin issuing a suite of disease-specific guidance documents on the development of specific gene therapy products to lay out modern and more efficient parameters — including new clinical measures — for the evaluation and review of gene therapy for different high-priority diseases where the platform is being targeted.”

Luxturna is approved for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy that leads to vision loss and may cause complete blindness in certain patients.

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm589467.htm




Good luck, Farrell

What happened here?

https://seekingalpha.com/article/4113899-spark-therapeutics-ignites-excitement-unanimous-adcom-panel-vote

Getting national news coverage right now

https://seekingalpha.com/article/4094276-spark-therapeutics-paves-way-one-time-treatments-hemophilia

https://seekingalpha.com/article/4087791-spark-therapeutics-opportunity-positive-phase-3-data

Our Spark Therapeutics $ONCE valuation models imply nice upside b4 earnings Wednesday:

Fair Value Source

Fantastic short opp here tgt $25-30 by 1Q 2017

ONCE bullish 58.14

macd crossups scan

GREAT NEWS NOT LOVING THE GAP FOR ENTRY ONCE

$ONCE

I hope everyone realizes how big of a deal this is. This is a company that has the ability to give people their sight back. This is just the beginning for Spark and their pipeline.

Positive Trial Three Data Announced

On October 5, 2015, Spark Therapeutics, Inc. (the “Company”) issued a press release announcing the top-line results of its pivotal Phase 3 trial of SPK-RPE65 for genetic blinding conditions.

$ONCE

CNBC coverage

http://finance.yahoo.com/video/could-spark-cure-blindness-215100008.html?soc_src=copy

- SA note -

ONCE - Spark has 70% odds of phase 3 success - Cowen.

• Shares could trade to $70 (implied upside 59%) if Phase 3 study of SPK-RPE65 succeeds, or fall to $10-$20 if it fails, firm says.
• Results are expected in October.

Spark Therapeutics Inc - News Release - Spark Therapeutics Announces Database Lock for SPK-RPE65 Phase 3 Clinical Trial and Expected Release of Top-Line Data in October.

http://ir.sparktx.com/mobile.view?c=253900&v=203&d=1&id=2086609

$ONCE recent news/filings

bullish

## source: finance.yahoo.com

Tue, 19 May 2015 17:04:26 GMT ~ SPARK THERAPEUTICS, INC. Financials


read full: http://finance.yahoo.com/q/is?s=once
*********************************************************

Mon, 11 May 2015 20:45:05 GMT ~ SPARK THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report


read full: http://biz.yahoo.com/e/150511/once10-q.html
*********************************************************

Wed, 06 May 2015 12:30:00 GMT ~ Spark Therapeutics Inc Earnings Call scheduled for 8:30 am ET today


read full: http://biz.yahoo.com/cc/1/150021.html
*********************************************************

Wed, 06 May 2015 12:07:13 GMT ~ SPARK THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and


read full: http://biz.yahoo.com/e/150506/once8-k.html
*********************************************************

Wed, 06 May 2015 12:00:00 GMT ~ Spark Therapeutics Reports First Quarter 2015 Results

[GlobeNewswire] - PHILADELPHIA -- Spark Therapeutics today announced financial results for the quarter ended March 31, 2015.

read full: http://finance.yahoo.com/news/spark-therapeutics-reports-first-quarter-120000114.html
*********************************************************

$ONCE charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$ONCE company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/ONCE/company-info
Ticker: $ONCE
OTC Market Place: Not Available
CIK code: not found
Company name: Spark Therapeutics, Inc.
Incorporated In:

$ONCE share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available

$ONCE extra dd links

Company name: Spark Therapeutics, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/ONCE/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/ONCE/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=ONCE+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=ONCE+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=ONCE+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/ONCE/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/ONCE/news - http://finance.yahoo.com/q/h?s=ONCE+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/ONCE/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/ONCE/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/ONCE/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/ONCE/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/ONCE/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/ONCE/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/ONCE/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/ONCE/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=ONCE+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/ONCE
DTCC (dtcc.com): http://search2.dtcc.com/?q=Spark+Therapeutics%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Spark+Therapeutics%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Spark+Therapeutics%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/ONCE/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/ONCE
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/ONCE/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/ONCE/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/ONCE/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/ONCE/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/ONCE/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/ONCE/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/ONCE/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=ONCE&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=ONCE
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/ONCE/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=ONCE+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=ONCE+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=ONCE
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=ONCE
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=ONCE+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/ONCE/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=ONCE+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/ONCE.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=ONCE
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/ONCE/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/ONCE/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/ONCE/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/ONCE/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/ONCE
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/ONCE
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/ONCE:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=ONCE
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ONCE



$ONCE DD Notes ~ http://www.ddnotesmaker.com/ONCE

Quarterly Report (10-q)

Date : 05/11/2015 @ 4:45PM
Source : Edgar (US Regulatory)
Stock : Spark Therapeutics, Inc. (MM) (ONCE)
Quote : $65.00 3.9 (6.38%) @ 8:10PM

http://ih.advfn.com/p.php?pid=nmona&article=66813233

Finally some news and communication

http://www.sparktx.com/sites/default/files/fields/press-release/clearside_collaboration_press_release_final.pdf

Whew a bit of a bounce back today

So this explains a lot... It's a bloodbath - http://www.thestreet.com/story/13126476/1/gene-therapy-stocks-on-watch-following-failure-of-celladons-heart-failure-trial.html

ONCE Currently down 18.5% in 7 days. Does support around 54.60-55.00 hold?

Blood Bath

The Chinese are shorting. They just got approval to do this last week and biotech is today being hit the hardest. ONCE was picked up by quite a few etfs and mutual funds and they are the ones being shorted by the Chinese hence an adverse reaction on the stock itself.

wow, why the huge drop? I don't see any news... just market pressure? who is selling into the bid?

Gonna get my chance :)

I can't see it dropping below 69.50 - that's where the resistance is. It seems to be resisting breaking and staying above 76-77.
Good luck! - Spark is a solid company in my portfolio

Thanks for the reply. I will be looking to get in on Monday/Tuesday. Hopefully the pullback stops around 68.70 - that looks to be my strike price but the chart may not let it get there.

I have personal interests in the science they are pursuing so I plan to establish a core holding and trade some on the side.

Good luck to you.